Coherus BioSciences (NASDAQ: CHRS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | -1.000 | -0.5200 | ||||
REV | 68.950M | 60.115M | -8.835M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Cogent Biosciences (NASDAQ:COGT), Eagle Pharmaceuticals (NASDAQ:EGRX), Immatics (NASDAQ:IMTX) and Sangamo Therapeutics (NASDAQ:SGMO).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by UBS on Tuesday, June 14, 2022. The analyst firm set a price target for 7.00 expecting CHRS to fall to within 12 months (a possible -6.67% downside). 6 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $7.5 last updated Today at June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.